Topline results were announced from a cardiovascular outcomes study evaluating oral semaglutide in patients with type 2 diabetes.

Investigational product demonstrated superior hemodialysis vascular access outcomes compared with autologous arteriovenous ...

Finerenone further reduces albuminuria in patients already on triple therapy for CKD with type 2 diabetes (SGLT2i, GLP-1 RA, ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

Dr Ubel’s call for ethical guidance comes amid rapid growth in private equity acquisition of physician practices. According to a 2023 report titled “Monetizing Medicine: Private Equity and Competition ...

Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...

Use vs non-use of sodium-glucose cotransporter 2 inhibitors by older patients with CKD stages 4-5D is significantly associated with reductions in all-cause mortality risk at 6, 12, and 60 months.

Elevated CRP levels in patients with ASCVD should prompt clinicians to screen and monitor patients for kidney injury. Elevated C-reactive protein levels in patients with atherosclerotic cardiovascular ...

West African individuals with just 1 allele variant in the APOL1 gene are at increased risk for chronic kidney disease (CKD), especially focal segmental ...

Racial disparities have persisted over the past 2 decades in access to preemptive living donor kidney transplantation, ...

Empagliflozin continues to provide cardiorenal benefit in patients with chronic kidney disease (CKD) for up to 12 months ...